Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Commentary|Articles|June 18, 2025
Hematologists Highlight Notable Insights From the 2025 EHA Congress
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.
Advertisement
Advertisement
The
Related to this article
A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Etentamig improved ORR and PFS vs standard therapies in triple-class exposed relapsed/refractory multiple myeloma.
Uma Borate, MBBS, MS, discusses data for different azacitidine and venetoclax schedules from the Beat AML master clinical trial.
MT027, an off-the-shelf B7-H3–directed CAR T-cell therapy, earned FDA fast track designation for recurrent glioblastoma.
Advertisement
Advertisement